CGS 200

Drug Profile

CGS 200

Alternative Names: CGS-200; Trans-capsaicin - CapGenesis

Latest Information Update: 05 Jan 2016

Price : $50

At a glance

  • Originator CapGenesis Therapeutics
  • Class Catechols; Monounsaturated fatty acids; Non-opioid analgesics; Polyunsaturated alkamides; Small molecules
  • Mechanism of Action TRPV1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Musculoskeletal disorders; Osteitis deformans; Osteomyelitis; Osteonecrosis; Osteosarcoma

Most Recent Events

  • 30 Nov 2015 Preclinical trials in Osteosarcoma, Osteonecrosis, Osteomyelitis, Musculoskeletal disorders, Osteitis deformans in USA (Topical) before November 2015
  • 30 Nov 2015 CapGenesis Therapeutics files orphan designation application with the US FDA and the EMA for Osteomyelitis, Osteosarcoma, Osteonecrosis, Paget's disease and Morton's neuroma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top